3 Reasons to Avoid Shares of Valeant Pharmaceuticals

The company has done everything right over the past five years. But this may not be a bet worth taking.

The Motley Fool

Over the past five years, few Canadian stocks have been on as nice a run as Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX). Since this time in 2009, the stock has returned over 60% per year to shareholders. The company is undeniably the darling of the Canadian healthcare sector.

On Thursday morning, the company again reported strong results. Cash earnings came in at $1.72 per share, up 35% year-over-year. Revenue jumped by 77% to $1.89 billion.

Furthermore, Valeant is confident it can succeed in its $50 billion takeover attempt of Allergan (NYSE: AGN), best known for anti-wrinkle treatment Botox. Given Valeant CEO Michael Pearson’s track record of great acquisitions, this would also likely be great news for shareholders. And in this case Mr. Pearson even has the endorsement of activist investor Bill Ackman.

But before you buy Valeant’s shares, there are some things you must consider. Below are the top three reasons to steer clear of Valeant stock.

1. Uncertainty

Valeant’s business model rests on making numerous acquisitions to fill its pipeline, something that the company has done very well thus far. But this means the future is always very uncertain for the company. What happens if no suitable targets can be found? Will Mr. Pearson still feel the need to act? Analysts routinely say that Valeant is the most difficult stock to make projections for.

Valeant’s stock currently trades at just over $140 per share, which is an expensive price, considering the company made less than $7 in cash earnings per share in 2013. The market is clearly pricing in future successful acquisitions. So this makes Valeant much more speculative than most stocks on the TSX.

2. Accounting issues

Valeant’s acquisitive business model naturally leads to accounting discrepancies. For example, the company hardly needs to spend any money at all on research and development, leading to margins that appear high.

Furthermore, many of the accounting measures that Valeant presents are adjusted numbers, rather than standard accounting figures. More specifically, measures such as adjusted operating cash flow and cash earnings per share strip out certain acquisition-related costs, even though these costs are a central part of the company’s business model.

To be clear, there is nothing fraudulent about these numbers. But it does require an extra level of caution and scrutiny from investors.

3. Other alternatives

Owning shares of Valeant is akin to handing money over to Mr. Pearson, and trusting him to spend it wisely. So far he has. But there are other companies that have just as good a track record. The best example in Canada is Constellation Software, where CEO Mark Leonard has an excellent track record of buying small software companies.

I am not saying that Valeant shares will go down, or even that they’re overpriced. But they are very speculative, and buying the shares is a bet simply not worth taking when there are so many great alternatives.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

woman stares at chocolate layer cake
Dividend Stocks

Power Corporation vs. Great-West Lifeco: Which Dividend Stock Would I Own?

Power Corporation gives you exposure to Great-West and more. I’d take Great-West directly when I want to know what’s funding…

Read more »

frustrated shopper at grocery store
Tech Stocks

Shopify Stock Is Down 16% in the Past Month: Should You Buy the Dip?

Shopify stock fell 16% recently. Discover the impact of interest rate hikes and market sentiment on Shopify's performance.

Read more »

dividend growth for passive income
Energy Stocks

Enbridge Has a New CEO and 31 Straight Dividend Hikes: Worth Buying?

With a new CEO taking charge, 31 consecutive annual dividend increases, and a $38 billion growth backlog, Enbridge could be…

Read more »

hot air balloon in a blue sky
Bank Stocks

Hot Take: This Is the Top Canadian Dividend Stock for Safety and Growth

Here's a safe Canadian dividend stock for investors seeking reliable income, financial stability, and long-term growth.

Read more »

a person watches a downward arrow crash through the floor
Dividend Stocks

Down Day, Wish List Ready: 3 Canadian Stocks to Keep Handy If You Have Cash to Invest

Market swings can catch you off guard, but be ready to take advantage of buying opportunities in a down day.

Read more »

View of high rise corporate buildings in the financial district of Toronto, Canada
Stocks for Beginners

Stantec Stock: Turning Infrastructure Spending Into a Long-Term Investment Case

A bigger infrastructure budget makes a good headline. Stantec’s backlog and earnings tell me whether shareholders are starting to benefit.

Read more »

Canadian Red maple leaves seamless wallpaper pattern
Dividend Stocks

How I’d Use a $20,000 TFSA to Start an Income Plan, Not Replace a Salary

A $20,000 TFSA can start paying part of a bill. Reinvesting those first dividends can give it a bigger job…

Read more »

A solar cell panel generates power in a country mountain landscape.
Investing

3 Top Canadian Stocks to Buy With $1,000

These Canadian stocks have solid growth prospects and are likely to outperform the broader Canadian equity market by a wide…

Read more »